Literature DB >> 29228201

Widespread brain tau and its association with ageing, Braak stage and Alzheimer's dementia.

Val J Lowe1, Heather J Wiste2, Matthew L Senjem1,3, Stephen D Weigand2, Terry M Therneau2, Bradley F Boeve4, Keith A Josephs4, Ping Fang1, Mukesh K Pandey1, Melissa E Murray5, Kejal Kantarci1, David T Jones1,4, Prashanthi Vemuri1, Jonathan Graff-Radford4, Christopher G Schwarz1, Mary M Machulda6, Michelle M Mielke2,4, Rosebud O Roberts2, David S Knopman4, Ronald C Petersen4, Clifford R Jack1.   

Abstract

See Herholz (doi:10.1093/brain/awx340) for a scientific commentary on this article.Autopsy data have proposed that a topographical pattern of tauopathy occurs in the brain with the development of dementia due to Alzheimer's disease. We evaluated the findings of tau-PET to better understand neurofibrillary tangle development as it is seen in cognitively unimpaired and impaired individuals. The evolution of Alzheimer's disease tauopathy in cognitively unimpaired individuals needs to be examined to better understand disease pathogenesis. Tau-PET was performed in 86 cognitively impaired individuals who all had abnormal amyloid levels and 601 cognitively unimpaired individuals. Tau-PET findings were assessed for relationships with clinical diagnosis, age, and regional uptake patterns relative to Braak stage. Regional and voxel-wise analyses were performed. Topographical findings from tau-PET were characterized using hierarchical clustering and clinical characteristic-based subcategorization. In older cognitively unimpaired individuals (≥50 years), widespread, age-related elevated tau signal was seen among those with normal or abnormal amyloid status as compared to younger cognitively unimpaired individuals (30-49 years). More frequent regional tau signal elevation throughout the brain was seen in cognitively unimpaired individuals with abnormal versus normal amyloid. Elevated tau signal was seen in regions that are considered high Braak Stage in cognitively unimpaired and cognitively impaired individuals. Hierarchical clustering and clinical characteristic-based categorizations both showed different patterns of tau signal between groups such as greater tau signal in frontal regions in younger onset Alzheimer's disease dementia participants (most of whom had a dysexecutive clinical presentation). Tau-PET signal increases modestly with age throughout the brain in cognitively unimpaired individuals and elevated tau is seen more often when amyloid brain accumulation is present. Tau signal patterns in cognitively unimpaired correspond to early Braak stage but also suggest tangle involvement in extra-medial temporal and extra-temporal regions that are considered more advanced in the Braak scheme even when amyloid negative. Our findings also suggest the possibility of widespread development of early tangle pathology rather than a pattern defined exclusively by adjacent, region-to-region spread, prior to onset of clinical symptoms. Distinct patterns of neurofibrillary tangle deposition in younger-onset Alzheimer's disease dementia versus older-onset Alzheimer's disease dementia provide evidence for variability in regional tangle deposition patterns and demonstrate that different disease phenotypes have different patterns of tauopathy. Pathological correlation with imaging is needed to assess the implications of these observations.
© The Author (2017). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Alzheimer’s disease; amyloid-PET; dementia; mild cognitive impairment; tau-PET

Mesh:

Substances:

Year:  2018        PMID: 29228201      PMCID: PMC5837250          DOI: 10.1093/brain/awx320

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  51 in total

1.  Examination of the validity of the hierarchical model of neuropathological staging in normal aging and Alzheimer's disease.

Authors:  H J Gertz; J Xuereb; F Huppert; C Brayne; M A McGee; E Paykel; C Harrington; E Mukaetova-Ladinska; T Arendt; C M Wischik
Journal:  Acta Neuropathol       Date:  1998-02       Impact factor: 17.088

2.  The behavioural/dysexecutive variant of Alzheimer's disease: clinical, neuroimaging and pathological features.

Authors:  Rik Ossenkoppele; Yolande A L Pijnenburg; David C Perry; Brendan I Cohn-Sheehy; Nienke M E Scheltens; Jacob W Vogel; Joel H Kramer; Annelies E van der Vlies; Renaud La Joie; Howard J Rosen; Wiesje M van der Flier; Lea T Grinberg; Annemieke J Rozemuller; Eric J Huang; Bart N M van Berckel; Bruce L Miller; Frederik Barkhof; William J Jagust; Philip Scheltens; William W Seeley; Gil D Rabinovici
Journal:  Brain       Date:  2015-07-02       Impact factor: 13.501

Review 3.  Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature.

Authors:  Peter T Nelson; Irina Alafuzoff; Eileen H Bigio; Constantin Bouras; Heiko Braak; Nigel J Cairns; Rudolph J Castellani; Barbara J Crain; Peter Davies; Kelly Del Tredici; Charles Duyckaerts; Matthew P Frosch; Vahram Haroutunian; Patrick R Hof; Christine M Hulette; Bradley T Hyman; Takeshi Iwatsubo; Kurt A Jellinger; Gregory A Jicha; Enikö Kövari; Walter A Kukull; James B Leverenz; Seth Love; Ian R Mackenzie; David M Mann; Eliezer Masliah; Ann C McKee; Thomas J Montine; John C Morris; Julie A Schneider; Joshua A Sonnen; Dietmar R Thal; John Q Trojanowski; Juan C Troncoso; Thomas Wisniewski; Randall L Woltjer; Thomas G Beach
Journal:  J Neuropathol Exp Neurol       Date:  2012-05       Impact factor: 3.685

4.  Modeling the relation between neurofibrillary tangles and intellectual status.

Authors:  C Duyckaerts; M Bennecib; Y Grignon; T Uchihara; Y He; F Piette; J J Hauw
Journal:  Neurobiol Aging       Date:  1997 May-Jun       Impact factor: 4.673

5.  Brain injury biomarkers are not dependent on β-amyloid in normal elderly.

Authors:  David S Knopman; Clifford R Jack; Heather J Wiste; Stephen D Weigand; Prashanthi Vemuri; Val J Lowe; Kejal Kantarci; Jeffrey L Gunter; Matthew L Senjem; Michelle M Mielke; Rosebud O Roberts; Bradley F Boeve; Ronald C Petersen
Journal:  Ann Neurol       Date:  2013-02-19       Impact factor: 10.422

6.  Antemortem MRI based STructural Abnormality iNDex (STAND)-scores correlate with postmortem Braak neurofibrillary tangle stage.

Authors:  Prashanthi Vemuri; Jennifer L Whitwell; Kejal Kantarci; Keith A Josephs; Joseph E Parisi; Maria S Shiung; David S Knopman; Bradley F Boeve; Ronald C Petersen; Dennis W Dickson; Clifford R Jack
Journal:  Neuroimage       Date:  2008-05-20       Impact factor: 6.556

7.  Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease.

Authors:  P V Arriagada; K Marzloff; B T Hyman
Journal:  Neurology       Date:  1992-09       Impact factor: 9.910

8.  Age-specific population frequencies of cerebral β-amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study.

Authors:  Clifford R Jack; Heather J Wiste; Stephen D Weigand; Walter A Rocca; David S Knopman; Michelle M Mielke; Val J Lowe; Matthew L Senjem; Jeffrey L Gunter; Gregory M Preboske; Vernon S Pankratz; Prashanthi Vemuri; Ronald C Petersen
Journal:  Lancet Neurol       Date:  2014-09-04       Impact factor: 44.182

9.  Tau positron emission tomographic imaging in aging and early Alzheimer disease.

Authors:  Keith A Johnson; Aaron Schultz; Rebecca A Betensky; J Alex Becker; Jorge Sepulcre; Dorene Rentz; Elizabeth Mormino; Jasmeer Chhatwal; Rebecca Amariglio; Kate Papp; Gad Marshall; Mark Albers; Samantha Mauro; Lesley Pepin; Jonathan Alverio; Kelly Judge; Marlie Philiossaint; Timothy Shoup; Daniel Yokell; Bradford Dickerson; Teresa Gomez-Isla; Bradley Hyman; Neil Vasdev; Reisa Sperling
Journal:  Ann Neurol       Date:  2015-12-15       Impact factor: 10.422

10.  Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.

Authors:  Michael J Pontecorvo; Michael D Devous; Michael Navitsky; Ming Lu; Stephen Salloway; Frederick W Schaerf; Danna Jennings; Anupa K Arora; Anne McGeehan; Nathaniel C Lim; Hui Xiong; Abhinay D Joshi; Andrew Siderowf; Mark A Mintun
Journal:  Brain       Date:  2017-03-01       Impact factor: 13.501

View more
  95 in total

Review 1.  The National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease: Perspectives from the Research Roundtable.

Authors:  David S Knopman; Samantha Budd Haeberlein; Maria C Carrillo; James A Hendrix; Geoff Kerchner; Richard Margolin; Paul Maruff; David S Miller; Gary Tong; Maria B Tome; Melissa E Murray; Peter T Nelson; Mary Sano; Niklas Mattsson; David L Sultzer; Thomas J Montine; Clifford R Jack; Hartmuth Kolb; Ronald C Petersen; Prashanthi Vemuri; Megan Zoschg Canniere; Julie A Schneider; Susan M Resnick; Gary Romano; Argonde Corien van Harten; David A Wolk; Lisa J Bain; Eric Siemers
Journal:  Alzheimers Dement       Date:  2018-04       Impact factor: 21.566

2.  MRI Outperforms [18F]AV-1451 PET as a Longitudinal Biomarker in Progressive Supranuclear Palsy.

Authors:  Jennifer L Whitwell; Nirubol Tosakulwong; Christopher G Schwarz; Hugo Botha; Matthew L Senjem; Anthony J Spychalla; J Eric Ahlskog; David S Knopman; Ronald C Petersen; Clifford R Jack; Val J Lowe; Keith A Josephs
Journal:  Mov Disord       Date:  2018-11-23       Impact factor: 10.338

3.  Progressive Tau Accumulation in Alzheimer Disease: 2-Year Follow-up Study.

Authors:  Hanna Cho; Jae Yong Choi; Hye Sun Lee; Jae Hoon Lee; Young Hoon Ryu; Myung Sik Lee; Clifford R Jack; Chul Hyoung Lyoo
Journal:  J Nucl Med       Date:  2019-03-29       Impact factor: 10.057

Review 4.  Imaging the evolution and pathophysiology of Alzheimer disease.

Authors:  William Jagust
Journal:  Nat Rev Neurosci       Date:  2018-11       Impact factor: 34.870

5.  [18 F]AV-1451 clustering of entorhinal and cortical uptake in Alzheimer's disease.

Authors:  Jennifer L Whitwell; Jonathan Graff-Radford; Nirubol Tosakulwong; Stephen D Weigand; Mary Machulda; Matthew L Senjem; Christopher G Schwarz; Anthony J Spychalla; David T Jones; Daniel A Drubach; David S Knopman; Bradley F Boeve; Nilüfer Ertekin-Taner; Ronald C Petersen; Val J Lowe; Clifford R Jack; Keith A Josephs
Journal:  Ann Neurol       Date:  2018-02-06       Impact factor: 10.422

6.  Subthreshold Amyloid Predicts Tau Deposition in Aging.

Authors:  Stephanie L Leal; Samuel N Lockhart; Anne Maass; Rachel K Bell; William J Jagust
Journal:  J Neurosci       Date:  2018-04-23       Impact factor: 6.167

7.  The role of age on tau PET uptake and gray matter atrophy in atypical Alzheimer's disease.

Authors:  Jennifer L Whitwell; Peter Martin; Jonathan Graff-Radford; Mary M Machulda; Matthew L Senjem; Christopher G Schwarz; Stephen D Weigand; Anthony J Spychalla; Daniel A Drubach; Clifford R Jack; Val J Lowe; Keith A Josephs
Journal:  Alzheimers Dement       Date:  2019-03-08       Impact factor: 21.566

8.  Effect Modifiers of TDP-43-Associated Hippocampal Atrophy Rates in Patients with Alzheimer's Disease Neuropathological Changes.

Authors:  Marina Buciuc; Alexandra M Wennberg; Stephen D Weigand; Melissa E Murray; Matthew L Senjem; Anthony J Spychalla; Bradley F Boeve; David S Knopman; Clifford R Jack; Kejal Kantarci; Joseph E Parisi; Dennis W Dickson; Ronald C Petersen; Jennifer L Whitwell; Keith A Josephs
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

9.  Atypical clinical features associated with mixed pathology in a case of non-fluent variant primary progressive aphasia.

Authors:  Jessica De Leon; Maria Luisa Mandelli; Amber Nolan; Zachary A Miller; Christie Mead; Christa Watson; Ariane E Welch; Maya L Henry; Viktoriya Bourakova; Renaud La Joie; Lynn P Bajorek; Lea Grinberg; Gil Rabinovici; Bruce L Miller; Maria Luisa Gorno-Tempini
Journal:  Neurocase       Date:  2019-04-29       Impact factor: 0.881

10.  Longitudinal neuroimaging biomarkers differ across Alzheimer's disease phenotypes.

Authors:  Irene Sintini; Jonathan Graff-Radford; Matthew L Senjem; Christopher G Schwarz; Mary M Machulda; Peter R Martin; David T Jones; Bradley F Boeve; David S Knopman; Kejal Kantarci; Ronald C Petersen; Clifford R Jack; Val J Lowe; Keith A Josephs; Jennifer L Whitwell
Journal:  Brain       Date:  2020-07-01       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.